ClinicalTrials.gg
RecruitingNCT06670963EpoAidUpdated Dec 27, 2024

Use of Epoetin Alfa and Iron Derisomaltose in Treatment of Anemia in Patients With Sepsis or Septic Shock: a Randomized Controlled Trial

A Phase 4 interventional study of Iron and EPO in Anemia, Sepsis and Septic Shock, sponsored by Piotr Czempik. Recruiting at 1 site in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-27.

Sponsored by Piotr Czempik · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies testing iron in Anemia — 3 open to participants now, 3 under way, none of them phase 3. Iron · Anemia.

Planned enrollment
19th of 34
200 · median 275
Started
2024
the only one that year
Phase 4
7 of 34
2 open now
Registered
32nd of 34
by date

Among the 34 studies testing iron in Anemia, this one is the 19th largest by planned enrollment, is the only one that started in 2024, is one of 7 in phase 4, and was the 32nd registered.

Anemia

1,812 studies on the registry are indexed under Anemia; 212 are open to participants now.

Browse Anemia studies →

Open to participants now

3 of the 34 studies testing iron in Anemia are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About iron

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 117 Anemia studies recruiting now, 66 (56%) set no upper age limit and 33 (28%) stop at 75 or younger; 32 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing iron in Anemia, or all of them as a file.
02

Study summary

Background Up to 66% of have anemia at the admission to the intensive care unit. This number increases to 95% after 72 hours of hospitalization in the intensive care unit due to illness and iatrogenic blood loss. Anemia worsens tissue oxygenation, especially in patietns with sepsis or septic shock, who already have blood flow issues. Instead of giving blood transfusions, which can have side effects, we aim to address the root causes of anemia in these patients. Sepsis can cause "inflammatory anemia" and combine with iron deficiency anemia. Current anemia treatments include drugs that stimulate red blood cell production and intravenous iron supplements. Some think that iron supplements can worsen infections by feeding pathogens, but this is not conclusively proven. Since transfused red blood cells (RBC) also contain iron, small doses of intravenous iron might help sepsis patients with iron deficiency.

There is a need for a study on the effects of epoetin alfa and iron derisomaltose on hemoglobin (Hb) levels in sepsis patients.

Hypothesis and Aim Treating anemia in sepsis patients could increase Hb levels and reduce RBC transfusions, improving patient outcomes. This study aims to evaluate the effects of epoetin alfa ± iron derisomaltose on Hb levels and RBC transfusion rates.

Primary Endpoints:

  1. Hb difference at study exit (discharge from ICU/death/bleeding/need for surgery/day 15 whatever comes first) and day 1 corrected for Hb increase due to possible RBC transfusion

Secondary Endpoints:

  1. Hb difference on days 8 and 1 corrected for Hb increase due to possible RBC transfusion
  2. Hb difference on days 15 and 1 corrected for Hb increase due to possible RBC transfusion
  3. number of blood transfusions
  4. percentage of patients receiving at least one blood transfusion
  5. actual vs. predicted mortality
  6. prevalence of deep vein thrombosis and pulmonary embolism
  7. mortality rates in ICU, hospital, 30-day, and 90-day.

Materials and Methods:

This will be a randomized controlled clinical trial recruting 200 patients

Inclusion Criteria:

  1. age ≥18
  2. diagnosed sepsis (Sepsis-3 definition) or septic shock (Septic Shock-3 definition)
  3. hemoglobin \<120 g/L for both sexes

Exclusion Criteria:

  1. bleeding
  2. decompensated liver disease
  3. inherited microcytic disorders
  4. macrocytosis
  5. contraindications to pharmacological prophylaxis for venous thromboembolism
  6. pregnancy
  7. allergy to epoetin alfa and/or iron derisomaltose.
  8. ferritin >800 ng/mL.
  9. inability to take consent

Study Group:

  1. epoetin alfa 50 u/kg IV (days 1, 3, 5, 8, 10, 12)
  2. iron derisomaltose 0.2g IV when RET-He \<29.3 pg (days 1, 3, 5, 8, 10, 12)
  3. algorithm for red blood cell transfusions

Control Group:

  1. algorithm for red blood cell transfusions

Laboratory Parameters:

Initial: interleukin-6, procalcitonin, C-reactive protein, creatinine, ammonia, blood urea nitrogen, aspartate aminotransferase, alanine aminotransferase, total bilirubin, complete blood count (CBC), reticulocytes (RET), ferritin, iron, transferrin.

Serial: CBC and RET (days 1, 3, 5, 8, 10, 12)

Read the detailed description

Project Description:

Project Title: The use of epoetin alfa and iron derisomaltose in treating anemia in patients with sepsis or septic shock in the ICU: a randomized controlled clinical trial.

Project Acronym: EpoAid

Theoretical Background and Rationale: Up to 66% of patients have anemia at admission to the intensive care unit. Additionally, many patients develop anemia during hospitalization in the intensive care unit due to illness and iatrogenic blood loss for laboratory diagnostics. After 72 hours 95% of intensive care unit patients are anemic. Anemia increases the risk of tissue oxygen deficiency, which is particularly important in sepsis or septic shock patients who may have peripheral perfusion disorders due to infection. Anemia should be treated causally because red blood cell transfusions can lead to adverse effects, including immunomodulation leading to innate immunity suppression, which is particularly significant in critically ill sepsis or septic shock patients. Anemia caused by sepsis is known as inflammatory anemia (AI). Sepsis patients often have mixed anemia, combining features of AI and iron deficiency anemia (IDA) - AI+IDA. Currently available treatments for mixed anemia include erythropoiesis-stimulating agents (ESA) and intravenous iron supplements (e.g., iron derisomaltose). Manufacturers of intravenous iron products contraindicate their use in infections since intravenous iron could theoretically exacerbate infections by stimulating pathogen growth. However, there is no conclusive data on this. Considering that stored red blood cells are also a source of iron that pathogens can use, it seems that fractional doses of intravenous iron could benefit sepsis patients with diagnosed iron deficiency. Additionally, ESA administration could cause functional iron deficiency, where small doses of intravenous iron might also be beneficial.

Attempts to use ESA and intravenous iron in the general ICU population have yielded inconclusive results due to methodological errors. In the IRONMAN study comparing iron carboxymaltose with placebo, no difference in transfusion rates (primary endpoint) was found, but higher Hb levels were observed at hospital discharge in the intervention group (107 vs. 100 g/L). This trial had some methodological flaws: intravenous iron was administered regardless of anemia etiology, red blood cell transfusion decisions were made by clinicians - there was no transfusion algorithm, and the average hospital stay was 11 days - maximal effect of intravenous iron is seen after 3-4 weeks, at least 2 weeks.

Iron deficiency diagnostics in sepsis patients must rely on parameters independent of the systemic inflammatory response since standard iron metabolism parameters (ferritin, transferrin saturation) are not useful here. Severe sepsis was an exclusion criterion in the IRONMAN study. Given the limitations of previous studies and the lack of research on the use of intravenous iron in sepsis patients, it is warranted to conduct a study evaluating the effect of epoetin alfa ± iron derisomaltose on Hb levels in sepsis or septic shock patients.

Hypothesis and Research Aim: Causal treatment of anemia in sepsis or septic shock patients may lead to increased Hb levels and reduced transfusion rates, potentially improving patient outcomes. This study aims to evaluate the effect of epoetin alfa ± iron derisomaltose on one primary and several secondary outcomes.

Materials and Methods: A randomized controlled clinical trial is planned. Blinding will be single due to the color (rusty) of the intervention drug (iron derisomaltose) and problems with complete blinding of the intervention. Randomization will be done using a computer generator of randomized numbers using block of 4. Two hundred patients will be recruited (100 in the experimental group, 100 in the control group). If a study subject starts bleeding or requires surgery (affects Hb levels and transfusion necessity - primary endpoints), the time until this event will be evaluated. Data collected: demographics (gender, age), infection site, length of stay (ICU, hospital), mortality (ICU, hospital, 30 days, 90 days). Blood loss for laboratory diagnostics will be monitored (calculation based on laboratory parameters ordered and test tube used). Pharmacological venous thromboembolism prophylaxis will be used in the experimental and contorol groups: enoxaparin 40 mg x 1 sc in patients with creatinine clearance ≥30 mL/min or dalteparin 5000 IU x 1 sc in patients with creatinine clearance \<30 mL/min, and a red blood cell transfusion decision algorithm will be employed.

Experimental group:

  1. epoetin alfa (Binocrit, Sandoz, Poland) given intravenously when Hb \<120 g/L, dosed by a study subject weight:

    • 2000 IU (\<60 kg)
    • 3000 IU (60-79 kg)
    • 4000 IU (80-99 kg)
    • 5000 IU (>100 kg) administered on days 1, 3, 5, 8, 10, 12
  2. iron derisomaltose (Monover, Pharmacosmos, Denmark) given intravenously at a dose of 0.2g when Hb \<120 g/L and RET-He \<29.3 pg, administered on days 1, 3, 5, 8, 10, 12
  3. red blood cell transfusion decision based on a proprietary decision algorithm. Binocrit will be stored at 2-8 °C. Before use, the drug will be stored at room temperature for 15 minutes. The drug is packaged in prefilled syringes; it will be mixed with 0.9% sodium chloride to a volume of 20 mL, then injected intravenously as a bolus, followed by a 20 mL 0.9% NaCl sodium chloride bolus to ensure immediate drug entry into the bloodstream. It is crucial to administer the entire dose without loss, as it is the primary intervention drug in this study. Monover is provided in 0.1g ampoules. The drug will be administered at a fixed dose of 0.2g when RET-HE \<29.3 pg on the scheduled administration day. The drug will be diluted with 0.9% NaCl to a volume of 50mL and administered in a brown 50mL syringe using an infusion pump at a rate of 60mL/h.

Control Group:

red blood cell transfusion decision based on a proprietary decision algorithm.

Monitored parameters:

  • initial lab parameters (extended): interleukin-6, procalcitonin, C-reactive protein, creatinine, ammonia, blood urea nitrogen, aspartate aminotransferase (AspAT), alanine aminotransferase, total bilirubin, complete blood count (CBC), reticulocytes (RET), ferritin, iron, transferrin.
  • serial measurements: Hb and hemoglobin equivalent in reticulocytes (RET-He) on the day of epoetin alfa ± iron derisomaltose administration.

Timeline: November 2024 - December 2026

Feasibility: given the number of ICU hospitalizations (approximately 400 per year) and the prevalence of sepsis/septic shock, it will be possible to enroll about 100 patients per year.

03

Conditions studied

  • Anemia
  • Sepsis
  • Septic Shock

Keywords

  • anemia
  • sepsis
  • septic shock
  • epoetin alfa
  • iron derisomaltose
  • red blood cell
  • hemoglobin
  • intensive care unit
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. age ≥18,
  2. diagnosed sepsis (Sepsis-3) or septic shock (Septic Shock-3),
  3. \<120 g/L in both sexes.

Exclusion criteria

Exclusion criteria:

  1. bleeding,
  2. decompensated liver disease,
  3. inherited microcytic disorders,
  4. macrocytosis,
  5. to pharmacological prophylaxis of VTE,
  6. pregnancy,
  7. allergy to epoetin alfa and/or iron derisomaltose,
  8. ferritin concentration >800 ng/mL,
  9. unable to take .
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Epoetin alfa +/- ferric derisomaltose

    Epoetin alfa 50 units/kg IV 3 times weekly and ferric derisomaltose 0.2g IV if reticulocyte hemoglobin equivalent \<29.3 pg

    Drug: Iron · Drug: EPO

  • Placebo comparator
    Placebo

    0.9% NaCl

    Drug: 0.9 % NaCl

Interventions

  • DrugIron

    Iron derisomaltose 0.2g IV if reticulocyte hemoglobin equivalent \<29.3 pg (lower limit for the local laboratory reference range for reticulocyte hemoglobin equivalent)

  • DrugErythropoietinStudies of ErythropoietinErythropoietin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Epoetin alfa 50 units/kg IV 3 times weekly

  • Drug0.9 % NaCl

    Volume of 0.9% NaCl identical as volume of medications used in experimental arm

06

What researchers measure

Primary outcomes

  1. Hemoglobin concentration difference at exit from the study

    The difference between hemoglobin concentration at exit from the study and day 1 corrected for Hb increase due to possible RBC transfusion \[RBC volume x RBC Hb concentration/study subject's blood volume (weight x 65 mL for women/weight x 75 mL for men)\]

    Time frame: From enrollment to day 15/death/discharge from ICU/bleeding episode/surgery whatever comes first

Secondary outcomes

  1. Hemoglobin concentration difference at 1 week

    The difference in hemoglobin concentration on days 8 and 1 corrected for Hb increase due to possible RBC transfusion \[RBC volume x RBC Hb concentration/study subject's blood volume (weight x 65 mL for women/weight x 75 mL for men)\]

    Time frame: From enrollment to day 8 (if a study subject still in the trial)

  2. Hemoglobin concentration difference at 2 weeks

    The difference in hemoglobin concentration between day 15 and day 1 corrected for Hb increase due to possible RBC transfusion \[RBC volume x RBC Hb concentration/study subject's blood volume (weight x 65 mL for women/weight x 75 mL for men)\]

    Time frame: From enrollment to day 15 (if a study subject still in the trial)

  3. Number of red blood cell units transfused

    Number of allogeneic red blood cell units transfused

    Time frame: From enrollment to day 15/death/discharge from ICU/bleeding episode/surgery whatever comes first

  4. Tranfusion rate

    Percentage of study subjects receiving at least one red blood cell unit

    Time frame: From enrollment to day 15/death/discharge from ICU/bleeding episode/surgery whatever comes first

  5. Deep vein thrombosis prevalence

    Number of deep vein thrombosis cases

    Time frame: From enrollment to day 15/death/discharge from ICU/bleeding episode/surgery whatever comes first

  6. Pulmonaly embolism prevalence

    Number of pulmonary embolism cases

    Time frame: From enrollment to day 15/death/discharge from ICU/bleeding episode/surgery whatever comes first

  7. Intensive care unit mortality

    Death during intensive care unit hospitalization (index hospitalization)

    Time frame: From enrollment to discharge from ICU

  8. 30-day mortality

    Death within 30 days of day 1

    Time frame: From enrollment to day 30

  9. 90-day mortality

    Death within 90 days of day 1

    Time frame: From enrollment to day 90

  10. Actual vs. predicted intensive care unit mortality

    Difference between actual intensive care unit mortality and intensive care unit mortality predicted by Sequential Organ Failure Assessment Score (index hospitalization)

    Time frame: From enrollment to discharge from ICU

  11. Actual vs. predicted intensive care unit mortality

    Difference between actual intensive care unit mortality and intensive care unit mortality predicted by Acute Physiology And Chronic Health Evaluation Score (index hospitalization)

    Time frame: From enrollment to discharge from ICU

  12. Actual vs. predicted intensive care unit mortality

    Difference between actual intensive care unit mortality and intensive care unit mortality predicted by Simplified Acute Physiology Score III (index hospitalization)

    Time frame: From enrollment to discharge from ICU

07

Study locations

1 of 1 sites recruiting
  • Uniwersyteckie Centrum Kliniczne im. prof. K. Gibińskiego Śląskiego Uniwersytetu Medycznego w Katowicach
    Katowice, 40-752, Poland
    Recruiting
    • Piotr F. Czempik, MD, PhD · Contactpczempik@sum.edu.pl · 00487894201
    • Agnieszka Wiórek, MD, PhD · Contactagnieszka.wiorek@gmail.com · 00487894201
    • Piotr F. Czempik, MD, PhD · Principal investigator
    • Agnieszka Wiórek, MD, PhD · Sub investigator
08

References and documents

Publications

  • Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016 Feb 23;315(8):801-10. doi: 10.1001/jama.2016.0287. PubMed 26903338 ↗
  • IRONMAN Investigators; Litton E, Baker S, Erber WN, Farmer S, Ferrier J, French C, Gummer J, Hawkins D, Higgins A, Hofmann A, De Keulenaer B, McMorrow J, Olynyk JK, Richards T, Towler S, Trengove R, Webb S; Australian and New Zealand Intensive Care Society Clinical Trials Group. Intravenous iron or placebo for anaemia in intensive care: the IRONMAN multicentre randomized blinded trial : A randomized trial of IV iron in critical illness. Intensive Care Med. 2016 Nov;42(11):1715-1722. doi: 10.1007/s00134-016-4465-6. Epub 2016 Sep 30. PubMed 27686346 ↗
  • Czempik PF, Wilczek D, Herzyk J, Krzych LJ. Hospital-Acquired Anemia in Patients Hospitalized in the Intensive Care Unit: A Retrospective Cohort Study. J Clin Med. 2022 Jul 6;11(14):3939. doi: 10.3390/jcm11143939. PubMed 35887702 ↗
  • Czempik PF, Pluta MP, Krzych LJ. Physiologic approach to red blood cell transfusion in non-bleeding critically ill patients. Arch Med Sci. 2022 Aug 30;18(5):1423-1425. doi: 10.5114/aoms/152217. eCollection 2022. No abstract available. PubMed 36160360 ↗
  • Czempik PF, Wiorek A. Comparison of Standard and New Iron Status Biomarkers: A Prospective Cohort Study in Sepsis Patients. Healthcare (Basel). 2023 Mar 30;11(7):995. doi: 10.3390/healthcare11070995. PubMed 37046922 ↗
  • Czempik PF, Wiorek A. Iron deficiency in sepsis patients managed with divided doses of iron dextran: a prospective cohort study. Sci Rep. 2023 Mar 31;13(1):5264. doi: 10.1038/s41598-023-32002-y. PubMed 37002279 ↗
  • Czempik PF, Wiorek A. Iron deficiency in sepsis patients based on reticulocyte hemoglobin and hepcidin concentration: a prospective cohort study. Arch Med Sci. 2023 May 24;19(3):805-809. doi: 10.5114/aoms/161802. eCollection 2023. PubMed 37313179 ↗

Individual participant data

Plan to share: No — Data privacy issues

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Dec 2026, 25 months after the start.

Of 60 non-industry phase 4 interventional studies under Anemia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 48. This study's planned 25 months is close to that.

Counting every sponsor, half of 74 studies reached it within 25 months; a quarter within 17 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2024
First posted
Nov 1, 2024
StartActual
Nov 10, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Apr 1, 2027
Last update
Dec 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06670963
Lead sponsor
Piotr Czempik
Responsible party
Piotr Czempik (Assistant Professor, MD, PhD, Medical University of Silesia) — Sponsor-investigator
First posted
Nov 1, 2024
Start date
Nov 10, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Apr 1, 2027 (estimated)
Last update
Dec 27, 2024

Study contacts

Piotr F. Czempik, MD, PhD
Contact
pczempik@sum.edu.pl
00487894201
Agnieszka Wiórek, MD, PhD
Contact
agnieszka.wiorek@gmail.com
00487894201

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iron

Start the discussion